...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biotechnology Advances: An International Review Journal >The case for plant-made veterinary immunotherapeutics
【24h】

The case for plant-made veterinary immunotherapeutics

机译：植物性兽医免疫疗法的情况

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval. Crown Copyright (C) 2016 Published by Elsevier Inc. All rights reserved.
机译：在食用动物生产中过量使用抗生素导致了对病原菌的抵抗，从而引发法规和消费者要求限制其使用。因此，需要经济有效且与集约化生产兼容的疾病控制替代方案。尽管疫苗被广泛使用和有效，但它们可抗少数动物疾病，因此需要开发新型疫苗和其他免疫疗法。在植物中重组生产这种蛋白质可以提供有效且安全的产品，可以以最少的处理量口服施用，并且可以以相对较低的资本投资容易地扩展。因此，本报告提倡使用植物来生产疫苗和抗体，以保护农场动物免受迄今为止用抗生素管理的疾病的侵害;并重点介绍了产品功效，竞争力和监管批准方面的最新进展。 Crown版权（C）2016，由Elsevier Inc.出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号